Spruce Biosciences(US:SPRB)2025-11-10 21:07Financial Performance - Cash and cash equivalents as of September 30, 2025, were $10.7 million, which does not include the $50.0 million from the recent financing[5] - Research and Development (R&D) expenses for Q3 2025 were $5.0 million, a decrease from $6.6 million in Q3 2024[5] - General and Administrative (G&A) expenses for Q3 2025 were $3.2 million, compared to $3.5 million in Q3 2024[8] - Total operating expenses for Q3 2025 were $8.2 million, down from $10.0 million in Q3 2024[8] - Net loss for Q3 2025 was $8.2 million, compared to a net loss of $8.7 million in Q3 2024[8] Financing Activities - Spruce Biosciences completed a $50.0 million private placement financing in October 2025, resulting in gross proceeds before offering expenses[5] - The company expects to fund its operating plan into the fourth quarter of 2026 with current cash and proceeds from the recent financing[5] Regulatory Developments - The company received Breakthrough Therapy Designation from the FDA for TA-ERT for the treatment of MPS IIIB in October 2025[5] - The biologics license application submission for TA-ERT is on track for the first quarter of 2026[1] Share Information - Common shares outstanding as of September 30, 2025, were 563,491[8]